Biopharmx Corp (NYSEAMERICAN:BPMX) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 5,070,482 shares, a decline of 0.7% from the November 15th total of 5,108,040 shares. Based on an average daily volume of 4,382,333 shares, the short-interest ratio is presently 1.2 days. Approximately 4.9% of the company’s shares are sold short.

In other Biopharmx news, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of Biopharmx stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Stephen Morlock bought 330,000 shares of Biopharmx stock in a transaction on Friday, November 24th. The shares were acquired at an average price of $0.15 per share, for a total transaction of $49,500.00. The disclosure for this purchase can be found here.

Shares of Biopharmx (NYSEAMERICAN BPMX) opened at $0.11 on Wednesday. Biopharmx has a 12-month low of $0.11 and a 12-month high of $0.90.

Biopharmx (NYSEAMERICAN:BPMX) last released its earnings results on Wednesday, September 13th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Biopharmx had a negative return on equity of 5,749.08% and a negative net margin of 22,005.88%.

Several research analysts have weighed in on BPMX shares. Maxim Group reiterated a “buy” rating and set a $1.50 target price on shares of Biopharmx in a report on Friday, December 8th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of Biopharmx in a report on Tuesday, September 19th.

ILLEGAL ACTIVITY NOTICE: “Biopharmx Corp (BPMX) Short Interest Update” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.